Sign In
Buy MRVI
$6.07
-0.160 (-2.57%)
At Close: Aug 10, 2026
Maravai LifeSciences Announces June 2021 Investor Conference Schedule
04:10pm, Wednesday, 26'th May 2021
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to pa
Tupperware Brands Corp And Redfin Corp Among Today's Top Shorts
11:16am, Tuesday, 11'th May 2021
The Dow fell 340 points, while the S&P 500 dipped 1.1%, and the Nasdaq dropped 1.2%. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to giv
Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q1 2021 Results - Earnings Call Transcript
11:18pm, Monday, 10'th May 2021
Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q1 2021 Results - Earnings Call Transcript
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
10:31am, Friday, 07'th May 2021
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Maravai LifeSciences To Host Earnings Conference Call on Monday, May 10, 2021
04:15pm, Tuesday, 13'th Apr 2021
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator
Maravai LifeSciences Announces Pricing of an Upsized Secondary Offering of Class A Common Stock by Selling Stockholders
08:20pm, Wednesday, 07'th Apr 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator
Maravai LifeSciences Announces Launch of Proposed Secondary Offering of Class A Common Stock by Selling Stockholders
05:30pm, Monday, 05'th Apr 2021
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator
Maravai LifeSciences Announces Preliminary Unaudited First Quarter Revenues and Income From Operations Range
04:05pm, Monday, 05'th Apr 2021
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and bi
New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing
MRVI Stock Price Increases Over 20% Pre-Market: Why It Happened
05:51am, Wednesday, 03'rd Mar 2021
The stock price of Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) has increased by over 20% pre-market. This is why it happened.
Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q4 2020 Results - Earnings Call Transcript
10:50pm, Tuesday, 02'nd Mar 2021
Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q4 2020 Results - Earnings Call Transcript
Maravai LifeSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Initiates 2021 Financial Guidance
04:05pm, Tuesday, 02'nd Mar 2021
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator
Maravai LifeSciences Announces March 2021 Investor Conference Schedule
07:05am, Monday, 01'st Mar 2021
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to
Maravai LifeSciences Expands Its Intellectual Property Portfolio
07:05am, Wednesday, 10'th Feb 2021
Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics
